(RTTNews) - Wednesday. Eli Lilly and Company (LLY) reported detailed results from the Phase 3 ACHIEVE-4 trial showing that Foundayo (orforglipron) demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in adults with type 2 diabetes and obesity or ov
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.